ID   EL4/E2
AC   CVCL_B6PK
SY   EL4-E2; EL-4/E2
DR   Wikidata; Q111733183
RX   PubMed=15687706;
RX   PubMed=17638915;
WW   https://wayne.technologypublisher.com/technology/36289
CC   Transfected with: HGNC; 3430; ERBB2.
CC   Transformant: ChEBI; CHEBI:59032; 7,12-dimethyltetraphene (DMBA; dimethylbenzanthracene).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: T-cell; CL=CL_0000084.
CC   Breed/subspecies: C57BL/6N.
DI   NCIt; C21925; Mouse precursor T cell lymphoblastic lymphoma/leukemia
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0255 ! EL4
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=15687706; DOI=10.3233/BD-2004-20106;
RA   Miller F.R., Jones R.F., Jacob J.B., Kong Y.-C.M., Wei W.-Z.;
RT   "From breast cancer immunobiology to her-2 DNA vaccine and autoimmune
RT   sequelae.";
RL   Breast Dis. 20:43-51(2004).
//
RX   PubMed=17638915; DOI=10.1158/0008-5472.CAN-06-4755;
RA   Jacob J.B., Kong Y.-C.M., Meroueh C., Snower D.P., David C.S., Ho Y.-S.,
RA   Wei W.-Z.;
RT   "Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and
RT   regulatory T cells.";
RL   Cancer Res. 67:7020-7027(2007).
//